When you invest, your capital is at risk.



Humans are drawn to self-improvement, and our data-rich world provides ample opportunities to optimise many aspects of life. The biohacking trend applies not only to the body, but also the mind.

Biohacking techniques often involve simply eating specific types of food or trying new exercises. But many are searching for further enhancements with ‘smart drugs’. 

Also known as nootropics, these are various substances that claim to improve the brain’s cognition. Having clear thoughts can lead to better decision making and reduced stress, so it’s no surprise the industry is worth about US$14b

Once associated with students and office workers seeking better focus and productivity, smart drugs are now advertised to help anyone from musicians with their memory and creativity to gamers wanting to improve reaction times.

It’s a wide array of products that includes prescription medications such as Adderall and Ritalin, for those with attention deficit hyperactivity disorder, or over-the-counter supplements like ginkgo biloba. 

Some manufacturers face criticisms about inconsistent regulations and for marketing what can effectively be pricey placebos. These concerns aren’t deterring major companies, with consumer goods giant Unilever ($UL) acquiring supplements firm Onnit in 2021. 

There are also significant efforts towards trying to recapture our childlike ability to absorb new information. The human brain has an estimated 100 billion neurons and we know the number of links between them and the rest of the body declines into adulthood. A multi-billion dollar industry is targeting degenerative diseases like Alzheimer’s, with firms like Eli Lilly ($LLY) and Biogen ($BIIB) bringing new drugs to the market.

Meanwhile, the wellness industry sees personalisation and prevention as central to its future, and smart drugs could play an important role. Customised vitamins are a reality, while there’s ongoing work into tailoring medicine to your DNA. To end where we started, smart drugs might just go full circle and help improve the body as well as the mind.


Want more?

You know what to do

Insights, trends and company deep dives delivered straight to your inbox.

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stake is the trading name of Hellostake Limited, a company registered in England and Wales (Company no. 11676409). Hellostake Limited is authorised and regulated by the UK Financial Conduct Authority under the Firm Reference Number 830771. Registered address: 85 Great Portland Street, London, W1W 7LT, United Kingdom.

When you invest, your capital is at risk.

The value of your investments can go down as well as up and you may receive back less than your original investment. Any advice is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate independent taxation and legal advice. The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services.

At Stake, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Please view ourTerms & Conditions,Privacy PolicyandDisclaimers before deciding to use or invest on Stake. By using the Stake website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance

Copyright © 2024 Stake. All rights reserved.